Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New cancer drug targets specific tumor mutations in early human trial
Disease control OngoingThis early-stage clinical trial is testing a new oral drug called KIN-2787, both alone and in combination with another cancer drug called binimetinib. The study aims to find safe doses and see if the treatment can shrink tumors in adults with advanced solid tumors (like lung canc…
Phase: PHASE1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 03, 2026 14:48 UTC
-
New drug duo targets advanced lung cancer in groundbreaking chinese trial
Disease control OngoingThis study is testing a combination of two drugs, encorafenib and binimetinib, for Chinese adults with a specific advanced form of lung cancer (BRAF V600E mutated NSCLC). The main goals are to see how well the drugs shrink tumors and to monitor their safety. The trial is for pati…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC